David Pagels, CEO at Dellner Couplers 2013-2021 Track record of driving profitable growth in industr...
Redeye regards Genovis’ Q1’22 report as solid and is encouraged to see continuously strong growth in...
Redeye notes a quarter well in-line with our estimates, with only slight cosmetic deviations to our ...
Redeye states that sales were lower than estimated and that weak profitability led to adjusted EBIT ...
Innofactor’s revenue development in Q1 was weakened by increased absences due to sickness, while pro...
Redeye still has an optimistic view on Impact Coatings and its prospects for long-term profitable gr...
Booming corporate lending and solid asset quality have spurred guidance upgrades among the Danish ba...
Strong sales and orders, but weak gross margins We make large EBIT cuts on the back of lower GMs Str...
Atria announced that it will sell its factory property in Malmö, Sweden.
EBIT 113% better than ABGSCe, partly driven by… …impressive pricing power with flat gross margin y-o...
Redeye leaves a comment on the Q1 report from Egetis Therapeutics released earlier this morning.
Recyctec publicerade idag den 26 april bolagets delårsrapport för Q1-22.
Tjänsteföretaget Coor väntas redovisa en tillväxt på omkring 20 procent under första kvartalet, driv...
Redeye raises the fair value of M.O.B.A. Network on the back of strong underlying growth and a stron...
Redeye comments on GiG ahead of its Q1-results (due 10 May) where we expect focus to be on Sportnco ...
Redeye adjusts its fair value range with a downward bias but continues to see meaningful upside to t...
SportnCo included in estimates from Q2’22 Change in our P&L structure – ‘22e adj.
Redeye raises its Base Case and forecasts slightly for ADDvise following a solid Q1 report.
Raute reports Q1 results on Apr 29. We continue to expect only break-even EBIT for this year.
Q1’22 organic rev. growth of 6% (cons. 8%) FY’22 guidance reiterated, indicating back-end loaded FY...
